Description
Market Report Coverage – Long-Read Sequencing Market
Market Segmentation
• Products (Systems, Kits and Assays, Software) and Services
• Technology (Single-Molecule Real-Time (SMRT) Sequencing, Nanopore Sequencing, Synthetic Long-Read Sequencing, and Others)
• Application (Oncology, Infectious Diseases, Rare Diseases, Genetic Disorders, Metabolic Disorders, and Translational Research)
• End User (Academic and Research Institutions, Pharma and Biotech Companies, Clinical Laboratories, Hospitals and Clinics, and Other End Users)
Regional Segmentation
• North America: U.S., Canada
• Europe: Germany, France, Italy, U.K., Spain, Netherland, Russia and Rest-of-the-Europe
• Asia-Pacific: Japan, China, India, Australia, South Korea, Singapore, and Rest-of-APAC
• Latin America: Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World (RoW)
Market Growth Drivers
• Decreasing Cost of Sequencing
• Global Increase in Cancer Prevalence
• Increasing Number of Population Genomics Initiatives
Market Challenges
• Lack of High Complexity Genomic Testing Centers in High Potential Markets
• Challenges Pertaining to Genomic Data Centers
• Scarcity of Knowledge Dissemination Pertaining to Advanced Diagnostic Capabilities
Market Opportunities
• Massive Scope for Adoption of Genomic Data Analysis Software in Emerging Nations
• Novel Diagnostic Applications
Key Companies Profiled
Agilent Technologies, Inc., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Bionano Genomics, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Longas Technologies Pty Ltd, Novogene Co., Ltd., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN N.V., Quantapore, Inc., and Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
• How is long-read sequencing revolutionizing the field of next generation sequencing?
• What are the major market drivers, challenges, and opportunities in the global long-read sequencing market?
• What are the underlying structures resulting in the emerging trends within the global long-read sequencing market?
• How is the COVID-19 pandemic impacting the global long-read sequencing market landscape?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to long-read sequencing?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region for the development of long-read sequencing?
• How is each segment of the market expected to grow during the forecast period 2021-2030, and what is the anticipated revenue to be generated by each segment? Following are the segments:
• Products (systems, kits, and assays, software) and services
• Technology (single-molecule real-time (SRMT) sequencing, nanopore sequencing, synthetic long-read sequencing, and others)
• Application (oncology, infectious diseases, rare diseases, genetic disorders, metabolic disorders, and translational research)
• End user (academic and research institutions, pharma and biotech companies, clinical laboratories, hospitals and clinics, and other end users)
• Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the companies in the region of their operation?
• Who are the leading players with significant offerings in the global long-read sequencing market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the current unmet needs that are being faced in the global long-read sequencing market?
Market Overview
Long-read sequencing is overcoming early limitations in throughput and accuracy. The sequencing methods are broadening their application domains in genomics and data analysis. Dedicated analysis tools that consider the characteristics of long-read data sequencing are required, while the fast pace of development of such tools can be overwhelming.
Long-read sequencing, or third-generation sequencing, offers several advantages over short-read sequencing. However, short-read sequencers such as Illumina’s NovaSeq, HiSeq, NextSeq, and MiSeq instruments, BGI’s MGISEQ and BGISEQ models, or Thermo Fisher’s Ion Torrent sequencers produce reads of up to 600 bases for long-read sequencing technologies routinely generate reads over 10 kb.
Long-read sequencing analysis is a process that helps researchers and clinicians to analyze and interpret data generated by modern genomics technologies, such as NGS and PCR. As sequencing technologies are producing millions of high-quality reads per run, the adoption of robust long-read sequencing solutions has increased significantly over the past few years.
Our healthcare experts have found long-read sequencing to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 21.15% over the forecast period of 2021-2030.
Factors fueling the growth of the market include a decrease in the cost of sequencing, a global increase in cancer prevalence, and an increase in the number of population genomics initiatives.
Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth. The lack of high complexity genomic testing centers in high potential markets, challenges pertaining to genomic data storage, and scarcity of knowledge dissemination pertaining to advanced diagnostic capabilities are the major challenges for the growth of the market.
Further, some of the opportunities, such as massive scope for adoption of genomic data analysis software in emerging nations, provide growth to the market.
Within the research report, the market has been segmented on the basis of products and services, technology, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the cases of cancer and genetic disorders on the global level has created a buzz among companies to invest in the advanced technologies of next-generation sequencing.
Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.
Global Industrial Microbiological QC Market: Focus on Market Offering, Technology Trends, Application, End User, Regulatory Framework, 13 Countries’ Analysis Competitive Analysis and Forecast, 2021-2031
Table of Contents
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Long-Read Sequencing Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 Market Overview
4.1 Market Definition
4.2 Market Footprint and Growth Potential
4.3 COVID-19 Impact on Global Long-Read Sequencing Market
5 Market Dynamics
5.1 Overview
5.2 Impact Analysis
5.3 Market Drivers
5.3.1 Decreasing Cost of Sequencing
5.3.2 Global Increase in Cancer Prevalence
5.3.3 Increasing Number of Population Genomics Initiatives
5.4 Market Restraints
5.4.1 Lack of High Complexity Genomic Testing Centers in High Potential Markets
5.4.2 Challenges Pertaining to Genomic Data Storage
5.4.3 Scarcity of Knowledge Dissemination Pertaining to Advanced Diagnostic Capabilities
5.5 Market Opportunities
5.5.1 Massive Scope for Adoption of Genomic Data Analysis Software in Emerging Nations
5.5.2 Novel Diagnostic Applications
6 Industry Insights
6.1 Overview
6.2 Legal Requirements and Framework in the U.S.
6.2.1 FDA Regulation
6.2.2 Centers for Medicare and Medicaid Services (CMS) Regulation
6.3 Legal Requirements and Framework in Europe
6.4 Legal Requirements and Framework in Asia-Pacific
6.4.1 China
6.4.2 Japan
7 Competitive Landscape
7.1 Acquisitions
7.2 Synergistic Activities
7.3 Product Launches and Upgradations
7.4 Market Share Analysis (by Company), 2019 and 2020
7.5 Growth Share Analysis
7.5.1 Growth Share Analysis (by Technology)
7.5.2 Growth Share Analysis (by Application)
8 Global Long-Read Sequencing Market (by Products and Services), $Million, 2020-2030
8.1 Overview
8.2 Products
8.2.1 Systems
8.2.2 Kits and Assays
8.2.3 Software
8.3 Services
9 Global Long-Read Sequencing Market (by Technology), $Million, 2020-2030
9.1 Overview
9.2 Single-Molecule Real-Time (SMRT) Sequencing
9.3 Nanopore Sequencing
9.4 Synthetic Long-Read Sequencing
9.5 Other Sequencing Technologies
10 Global Long-Read Sequencing Market (by Application), $Million, 2020-2030
10.1 Overview
10.2 Oncology
10.3 Infectious Diseases
10.4 Rare Diseases
10.5 Genetic Disorders
10.6 Metabolic Disorders
10.7 Translational Research
11 Global Long-Read Sequencing Market (by End User), $Million, 2020-2030
11.1 Overview
11.2 Academic and Research Institutions
11.3 Pharma and Biotech Companies
11.4 Clinical Laboratories
11.5 Hospitals and Clinics
11.6 Other End Users
12 Global Long-Read Sequencing Market (by Region), $Million, 2020-2030
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 U.K.
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 Netherlands
12.3.7 Russia
12.3.8 Rest-of-Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Australia
12.4.6 Singapore
12.4.7 Rest-of-Asia-Pacific
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest-of-Latin-America
12.6 Rest-of-the-World (RoW)
13 Company Profiles
13.1 Overview
13.2 Agilent Technologies, Inc.
13.2.1 Company Overview
13.2.2 Role of Agilent Technologies, Inc. in the Global Long-Read Sequencing Market
13.2.3 Financials
13.2.4 Key Insights About Financial of the Company
13.2.5 SWOT Analysis
13.3 Beijing Genomics Institute (BGI) Genomics Co., Ltd
13.3.1 Company Overview
13.3.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Long-Read Sequencing Market
13.3.3 SWOT Analysis
13.4 Bionano Genomics, Inc.
13.4.1 Company Overview
13.4.2 Role of Bionano Genomics, Inc. in the Global Long-Read Sequencing Market
13.4.3 Financials
13.4.4 Key Insights About Financial Health of the Company
13.4.5 SWOT Analysis
13.5 F. Hoffmann-La Roche Ltd
13.5.1 Company Overview
13.5.2 Role of F. Hoffmann-La Roche Ltd in the Global Long-Read Sequencing Market
13.5.3 Financials
13.5.4 Key Insights About Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Illumina, Inc.
13.6.1 Company Overview
13.6.2 Role of Illumina, Inc. in the Global Long-Read Sequencing Market
13.6.3 Financials
13.6.4 Key Insights About Financial Health of the Company
13.6.5 SWOT Analysis
13.7 Longas Technologies Pty Ltd
13.7.1 Company Overview
13.7.2 Role of Longas Technologies Pty Ltd in the Global Long-Read Sequencing Market
13.7.3 SWOT Analysis
13.8 Novogene Co., Ltd.
13.8.1 Company Overview
13.8.2 Role of Novogene Co., Ltd. in the Global Long-Read Sequencing Market
13.8.3 SWOT Analysis
13.9 Oxford Nanopore Technologies, Inc.
13.9.1 Company Overview
13.9.2 Role of Oxford Nanopore Technologies, Inc. in the Global Long-Read Sequencing Market
13.9.3 SWOT Analysis
13.1 Pacific Biosciences of California, Inc.
13.10.1 Company Overview
13.10.2 Role of Pacific Biosciences of California, Inc. in the Global Long-Read Sequencing Market
13.10.3 Financials
13.10.4 Key Insights About Financial Health of the Company
13.10.5 SWOT Analysis
13.11 PerkinElmer, Inc.
13.11.1 Company Overview
13.11.2 Role of PerkinElmer Inc. in the Global Long-Read Sequencing Market
13.11.3 Financials
13.11.4 SWOT Analysis
13.12 QIAGEN N.V.
13.12.1 Company Overview
13.12.2 Role of QIAGEN N.V. in the Global Long-Read Sequencing Market
13.12.3 Financials
13.12.4 Key Insights About Financial Health of the Company
13.12.5 SWOT Analysis
13.13 Quantapore, Inc.
13.13.1 Company Overview
13.13.2 Role of the Quantapore, Inc. in the Global Long-Read Sequencing Market
13.13.3 SWOT Analysis
13.14 Thermo Fisher Scientific Inc.
13.14.1 Company Overview
13.14.2 Role of Thermo Fisher Scientific Inc. in the Global Long-Read Sequencing Market
13.14.3 Financials
13.14.4 Key Insights About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 Snapshot
13.15.1 Stratos Genomics
13.15.1.1 Company Overview
13.15.1.2 Role of Stratos Genomics in the Global Long-Read Sequencing Market
List of Tables
Table 5.1: Likert Scale
Table 5.2: Impact Analysis of Market Drivers
Table 5.3: Impact Analysis of Market Restraints
Table 8.1: Systems Offered by Key Players
Table 8.2: Kits and Assays Offered by Key Players
Table 8.3: Services Offered by Key Players
List of Figures
Figure 1: Annual NIH Funding in Human Genomics Research, FY2013-FY2019
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Long-Read Sequencing Market
Figure 3: Global Long-Read Sequencing Market (by Products and Services), $Million, 2020 vs. 2030
Figure 4: Global Long-Read Sequencing Market (by Technology), $Million, 2020 vs. 2030
Figure 5: Global Long-Read Sequencing Market (by Application), $Million, 2020 vs. 2030
Figure 6: Global Long-Read Sequencing Market (by End User), $Million, 2020 vs. 2030
Figure 7: Global Long-Read Sequencing Market Snapshot
Figure 2.1: Global Long-Read Sequencing Market: Segmentation
Figure 3.1: Global Long-Read Sequencing Market: Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Long-Read Sequencing Market, $Million, 2020-2030
Figure 4.2: Global Long-Read Sequencing Market: COVID-19 Impact
Figure 5.1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing, 2009-2025
Figure 5.2: Global Cancer Burden, 2018
Figure 6.1: FDA IVD Classification and Regulatory Process
Figure 6.2: Key Changes in EU IVD Regulation 2017/746
Figure 6.3: Medical Device Regulatory Approval Process in China
Figure 7.1: Share of Key Developments and Strategies, January 2017–May 2021
Figure 7.2: Share of Acquisitions (by Company), January 2017-May 2021
Figure 7.3: Synergistic Activities Share (by Company), January 2018-May2021
Figure 7.4: Number of Product Launches and Upgradations (by Company), January 2017–May 2021
Figure 7.5: Market Share Analysis for Global Long-Read Sequencing Market, 2019 and 2020
Figure 7.6: Growth Share Analysis for Global Long-Read Sequencing Market (by Technology), 2020-2031
Figure 7.7: Growth Share Analysis for Global Long-Read Sequencing Market (by Application), 2020-2031
Figure 8.1: Global Long-Read Sequencing Market (by Products and Services)
Figure 8.2: Global Long-Read Sequencing Market (by Products and Services), 2020-2030
Figure 8.3: Global Long-Read Sequencing Market (Products), $Million, 2020-2030
Figure 8.4: Global Long-Read Sequencing Market (Systems), $Million, 2020-2030
Figure 8.5: Global Long-Read Sequencing Market (Kits and Assays), $Million, 2020-2030
Figure 8.6: Global Long-Read Sequencing Market (Software), $Million, 2020-2030
Figure 8.7: Global Long-Read Sequencing Market (Services), $Million, 2020-2030
Figure 8.8: Global Long-Read Sequencing Market (by Service), 2020-2030
Figure 9.1: Global Long-Read Sequencing Market (by Technology)
Figure 9.2: Global Long-Read Sequencing Market (by Technology), 2020-2030
Figure 9.3: Global Long-Read Sequencing Market (SMRT Sequencing), $Million, 2020-2030
Figure 9.4: Global Long-Read Sequencing Market (Nanopore Sequencing), $Million, 2020-2030
Figure 9.5: Global Long-Read Sequencing Market (Synthetic Long-Read Sequencing), $Million, 2020-2030
Figure 9.6: Global Long-Read Sequencing Market (Other Sequencing Technologies), $Million, 2020-2030
Figure 10.1: Global Long-Read Sequencing Market (by Application)
Figure 10.2: Global Long-Read Sequencing Market (by Application), $Million, 2020-2030
Figure 10.3: Global Long-Read Sequencing Market (Oncology), $Million, 2020-2030
Figure 10.4: Global Long-Read Sequencing Market (Infectious Diseases), $Million, 2020-2030
Figure 10.5: Global Long-Read Sequencing Market (Rare Diseases), $Million, 2020-2030
Figure 10.6: Global Long-Read Sequencing Market (Genetic Disorders), $Million, 2020-2030
Figure 10.7: Global Long-Read Sequencing Market (Metabolic Disorders), $Million, 2020-2030
Figure 10.8: Global Long-Read Sequencing Market (Translational Research), $Million, 2020-2030
Figure 11.1: Global Long-Read Sequencing Market (by End User)
Figure 11.2: Global Long-Read Sequencing Market (by End User), $Million, 2020-2030
Figure 11.3: Global Long-Read Sequencing Market (Academic and Research Institutions), $Million, 2020-2030
Figure 11.4: Global Long-read Sequencing Market (Pharma and Biotech Companies), $Million, 2020-2030
Figure 11.5: Global Long-read Sequencing Market (Clinical Laboratories), $Million, 2020-2030
Figure 11.6: Global Long-read Sequencing Market (Hospitals and Clinics), $Million, 2020-2030
Figure 11.7: Global Long-Read Sequencing Market (Other End Users), $Million, 2020-2030
Figure 12.1: Global Long-Read Sequencing Market (by Region), 2020 and 2030
Figure 12.2: Global Long-Read Sequencing Market (by Region), $Million, 2020-2030
Figure 12.3: Global Long-Read Sequencing Market (by Region), 2020-2030
Figure 12.4: North America Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.5: North America: Market Dynamics
Figure 12.6: North America Long-Read Sequencing Market (by Country), $Million, 2020-2030
Figure 12.7: U.S. Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.8: Canada Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.9: Europe Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.10: Europe: Market Dynamics
Figure 12.11: Europe Long-Read Sequencing Market (by Country), $Million, 2020-2030
Figure 12.12: Germany Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.13: U.K. Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.14: France Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.15: Italy Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.16: Spain Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.17: Netherlands Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.18: Russia Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.19: Rest-of-Europe Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.20: Asia-Pacific Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.21: APAC: Market Dynamics
Figure 12.22: APAC Long-Read Sequencing Market (by Country), $Million, 2020-2030
Figure 12.23: China Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.24: Japan Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.25: India Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.26: South Korea Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.27: Australia Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.28: Singapore Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.29: RoAPAC Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.30: Latin America Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.31: Latin America: Market Dynamics
Figure 12.32: Latin America Long-Read Sequencing Market (by Country), $Million, 2020-2030
Figure 12.33: Brazil Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.34: Mexico Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.35: Rest-of-Latin America Long-Read Sequencing Market, $Million, 2020-2030
Figure 12.36: RoW Long-Read Sequencing Market, $Million, 2020-2030
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Agilent Technologies, Inc.: Product Portfolio
Figure 13.3: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 13.4: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 13.5: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 13.6: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 13.7: Agilent Technologies, Inc.: SWOT Analysis
Figure 13.8: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Product Portfolio
Figure 13.9: Beijing Genomics Institute (BGI) Genomics Co., Ltd.: SWOT Analysis
Figure 13.10: Bionano Genomics, Inc.: Product Portfolio
Figure 13.11: Bionano Genomics, Inc.: Overall Financials, 2018-2020
Figure 13.12: Bionano Genomics, Inc.: R&D Expenditure, 2018-2020
Figure 13.13: Bionano Genomics, Inc.: SWOT Analysis
Figure 13.14: F. Hoffmann-La Roche Ltd: Portfolio
Figure 13.15: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
Figure 13.16: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2018-2020
Figure 13.17: F. Hoffmann-La Roche Ltd: Sales (by Region), 2018-2020
Figure 13.18: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 13.19: F. Hoffmann-La Roche: SWOT Analysis
Figure 13.20: Illumina, Inc.: Overall Financials, 2018-2020
Figure 13.21: Illumina, Inc.: Revenue (by Segment), 2018-2020
Figure 13.22: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 13.23: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 13.24: Illumina, Inc.: SWOT Analysis
Figure 13.25: Longas Technologies Pty Ltd: Product Portfolio
Figure 13.26: Longas Technologies Pty Ltd: SWOT Analysis
Figure 13.27: Novogene Corporation: SWOT Analysis
Figure 13.28: Oxford Nanopore Technologies, Inc.: Product Portfolio
Figure 13.29: Oxford Nanopore Technologies, Inc.: SWOT Analysis
Figure 13.30: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 13.31: Pacific Biosciences of California, Inc.: Overall Financials, 2018-2020
Figure 13.32: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2018-2020
Figure 13.33: Pacific Biosciences of California, Inc.: Revenue (by Region), 2018-2020
Figure 13.34: Pacific Biosciences of California, Inc.: R&D Expenditure, 2018-2020
Figure 13.35: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 13.36: PerkinElmer, Inc.: Overall Financials, 2018-2020
Figure 13.37: PerkinElmer, Inc.: SWOT Analysis
Figure 13.38: QIAGEN N.V.: Portfolio
Figure 13.39: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 13.40: QIAGEN N.V.: Revenue (by Segment), 2018-2020
Figure 13.41: QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 13.42: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 13.43: QIAGEN N.V.: SWOT Analysis
Figure 13.44: Quantapore, Inc.: Product Portfolio
Figure 13.45: Quantapore, Inc.: SWOT Analysis
Figure 13.46: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 13.47: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 13.48: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018-2020
Figure 13.49: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 13.50: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 13.51: Thermo Fisher Scientific Inc.: SWOT Analysis
